Investigating how certain factors drive lethal prostate cancer
Official title: Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors
Funded at Mayo Clinic Rochester · NIH-11030814 · Data updated 2026-11-12
This study is looking at how a specific protein called GATA2 affects the growth and spread of advanced prostate cancer, with the hope that understanding this could help develop new treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $532,649 |
| NIH project number | 5R01CA280999-02 |
| Project ID | NIH-11030814 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are American men diagnosed with advanced or metastatic prostate cancer, particularly those whose disease has become resistant to standard therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind advanced prostate cancer, particularly how a master regulator transcription factor called GATA2 contributes to the disease's progression. By studying the role of GATA2 in cancer cell behavior, the research aims to uncover how it influences the aggressiveness and metastatic potential of prostate cancer. The approach includes advanced computational and functional studies to analyze gene expression and cellular behavior in prostate cancer cells. Patients may benefit from insights that could lead to new therapeutic strategies targeting these mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving lethal prostate cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting transcription factors in cancer treatment, suggesting that this approach may lead to significant advancements in managing lethal prostate cancer.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.